| 02.07 13:51 | dpa-AFX: J&J Reports Positive Data From Phase 3 CARTITUDE-4 Study Of Carvykti In Multiple Myeloma |
| 02.07 13:35 | dpa-AFX: *JOHNSON & JOHNSON REPORTS POSITIVE PHASE 3 RESULTS FOR CARVYKTI IN RELAPSED MULTIPLE MYELOMA |
| 01.07 07:31 | dpa-AFX: Sandoz To Commercialize Samsung Bioepis' FDA Approved Biosimilar Pyzchiva In US |
| 28.06 17:14 | dpa-AFX: J&J: Rybrevant In Combination Gets Approval In Europe For First-Line Treatment Of NSCLC |
| 28.06 16:33 | dpa-AFX: *J&J : RYBREVANT COMBINATION APPROVED IN EUROPE FOR FIRST-LINE TREATMENT OF NSCLC |
| 28.06 13:58 | dpa-AFX: Janssen-Cilag Says CHMP Recommended Balversa For Urothelial Carcinoma |
| 28.06 13:37 | dpa-AFX: *JANSSEN CILAG : CHMP BACKS BALVERSA FOR ADVANCED UROTHELIAL CARCINOMA TREATMENT |
| 21.06 13:33 | dpa-AFX: *JOHNSON & JOHNSON CLOSES ACQUISITION OF PRIVATELY-HELD BIOTECHNOLOGY COMPANY PROTEOLOGIX |
| 21.06 03:00 | dpa-AFX: Johnson & Johnson Seeks FDA Approval For Tremfya For Moderate To Severe Crohn's Disease |
| 20.06 14:32 | dpa-AFX: Johnson & Johnson: TREMFYA Phase 3 Study Meets Primary And Secondary Endpoints |
| 20.06 14:10 | dpa-AFX: *J&J : TREMFYA PHASE 3 CROHN'S DISEASE STUDY ACHIEVES ALL PRIMARY AND SECONDARY ENDPOINTS |
| 17.06 15:25 | dpa-AFX: J&J Submits BLA For Subcutaneous Amivantamab Combination In EGFR-mutated NSCLC Patients |
| 17.06 14:02 | dpa-AFX: *J&J :SUBCUTANEOUS AMIVANTAMAB BLA SUBMITTED TO FDA FOR PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER |
| 14.06 14:26 | dpa-AFX: Johnson & Johnson Reports Long-term Data From Phase 1/2 Study With TALVEY |
| 14.06 14:03 | dpa-AFX: *J&J: TALVEY STUDY REVEALS HIGHLY DURABLE RESPONSES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| 30.05 13:52 | dpa-AFX: *GOLDMAN NIMMT JOHNSON & JOHNSON MIT 'NEUTRAL' WIEDER AUF - ZIEL 160 USD |
| 30.05 13:52 | dpa-AFX: *GOLDMAN REINITIATES JOHNSON & JOHNSON WITH 'NEUTRAL' - PRICE TARGET 160 USD |
| 28.05 14:13 | dpa-AFX: Johnson & Johnson To Acquire Rights To Numab Therapeutics' Clinical-Stage Bispecific Antibody NM26 |
| 28.05 13:43 | dpa-AFX: *J&J TO BUY ATOPIC DERMATITIS BISPECIFIC FROM NUMAB FOR ABOUT $1.25 BLN |
| 28.05 13:41 | dpa-AFX: *JOHNSON & JOHNSON TO ACQUIRE CLINICAL-STAGE BISPECIFIC FOR ATOPIC DERMATITIS |
|
|
